Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
Sponsor: Vega Therapeutics, Inc
Summary
This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
Official title: A Prospective, Multicenter, Open-label, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Prophylactic VGA039 in Adolescent and Adult Patients With Von Willebrand Disease (VIVID-6)
Key Details
Gender
All
Age Range
12 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-10-15
Completion Date
2028-10
Last Updated
2026-09-14
Healthy Volunteers
No
Conditions
Interventions
VGA039
VGA039 SC administered for 49-weeks during the interventional phase following a 24-week observational period.
Locations (32)
Arkansas Children's Hospital
Little Rock, Arkansas, United States
Luskin Orthopaedic Institute For Children
Los Angeles, California, United States
Stanford University
Palo Alto, California, United States
UC Davis Medical Center
Sacramento, California, United States
University of California San Francisco
San Francisco, California, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Emory University Hospital
Atlanta, Georgia, United States
Children's Healthcare of Atlanta
Atlanta, Georgia, United States
University of Michigan Health
Ann Arbor, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Science 37, Inc. (Virtual Clinical MetaSite)
Morrisville, North Carolina, United States
Hemophilia Center of Western PA
Pittsburgh, Pennsylvania, United States
UT Southwestern Children's Hospital
Dallas, Texas, United States
Washington Center for Bleeding Disorders
Seattle, Washington, United States
Royal Prince Alfred Hospital, Institute of Haematology
Sydney, New South Wales (nsw), Australia
Royal Brisbane & Women's Hospital (RBWH), Queensland Haemophilia Centre
Brisbane, Queensland, Australia
The Alfred Hospital (Alfred Health),Monash University
Melbourne, Victoria, Australia
Medical University of Vienna
Vienna, Austria
Multihemo - Oncoclínicas
Recife, Pernambuco, Brazil
Centro de Hemoterapia e Hematologia do Rio de Janeiro (HEMORIO)
Rio de Janeiro, Rio de Janeiro, Brazil
emocentro UNICAMP (Centro de Hematologia e Hemoterapia da UNICAMP), University of Campinas (UNICAMP)
Campinas, São Paulo, Brazil
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)
São Paulo, São Paulo, Brazil
K Eristavi National Center of Experimental and Clinical Surgery (ქირურგიის ეროვნული ცენტრი)
Tbilisi, Georgia
Vivantes Klinikum im Friedrichshain
Berlin, Germany
Frankfurt University Hospital (Universitätsmedizin Frankfurt)
Frankfurt, Germany
St. James's Hospital, National Coagulation Centre
Dublin, Dublin, Ireland
University of Milan
Milan, Milan, Italy
Azienda Ospedaliero-Universitaria Careggi (Careggi University Hospital)
Florence, Italy
Worthwhile Clinical Trials Lakeview Hospital
Benoni, Gauteng, South Africa
Charlotte Maxeke Johannesburg Academic Hospital School of Pathology Clinical Haematologist
Johannesburg, South Africa
Imperial College Healthcare NHS Trust, Hammersmith Hospital
London, Greater London, United Kingdom
Royal Free London NHS Foundation Trust,
London, London, United Kingdom